Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome antibody Antibody titers coronavirus coronavirus disease Course COVID-19 Efficacy examined first vaccination immune response Infection Neutralizing activity Neutralizing titer onset of disease Patient SARS-CoV-2 shown single dose vaccination [DOI] 10.1016/j.jiac.2022.08.026 PMC 바로가기
IgG-RBD Response Due to Inactivated SARS-CoV-2 Vaccine: Alteration in D-Dimer and Fibrinogen Concentrations, Association with Comorbidities and Adverse EffectsArticle Published on 2022-11-032022-11-15 Journal: Laboratory medicine [Category] SARS, 진단, [키워드] Adverse alteration appear blood sample both groups changes in Concentration CoronaVac Coronavirus infection COVID-19 COVID-19 infection D-dimer D-dimer level domain Effect effective fibrinogen fibrinogen level first vaccination IgG Immunoglobulin individual infected individual Infection Mask Measures Participants Protective response Safe SARS-CoV-2 second dose second vaccination Side effects significantly higher statistically subject vaccination Vaccine was obtained were measured [DOI] 10.1093/labmed/lmac047 PMC 바로가기
Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseasesArticle Published on 2022-11-022022-11-15 Journal: Rheumatology (Oxford, England) [Category] SARS, 진단, 치료기술, [키워드] adverse event childhood-onset rheumatic disease Chinese Cohort COVID-19 COVID-19 infection cPass™ cut-off defined disease Disease activity dose Efficacy evaluate female first vaccination humoral immunogenicity immunogenicity increased the risk inhibition median medication Most patient mounted mRNA vaccination mRNA vaccine neutralization Neutralizing antibodies Neutralizing antibody response neutralizing response not affect Paediatric age paediatric rheumatology Patient positive predictor proportion remained response rheumatic disease SARS-CoV-2 SARS-CoV-2 vaccine second vaccination Serious Adverse Event serious complication Seven subgroup analysis symptomatic the SARS-CoV-2 the vaccine two-dose regimen vaccination Vaccine vaccine efficacy vaccine safety were assessed [DOI] 10.1093/rheumatology/keac105 PMC 바로가기
Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant RecipientsArticle Published on 2022-11-012022-11-15 Journal: Clinical gastroenterology and hepatology : the off [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] acute respiratory syndrome anti-S anti-SARS-CoV-2 antibody Antibody Response Antibody titer cellular Cellular immune response coronavirus COVID-19 defined domain dose filtration first vaccination HCs healthy control humoral immune response Immunosuppression increase increase in investigated liver liver transplant liver transplant recipients LTR LTRs Lymphocyte count mRNA mRNA-based non-responders Odds ratio Patient Prospective Study RBD recipient responders response risk factor SARS-CoV-2 SARS-CoV-2 vaccination second vaccination Seroconversion seronegative seropositive spike-specific T-cell response T cells the median Third and Fourth SARS-CoV-2 Vaccination. Transplant vaccination Vaccinations [DOI] 10.1016/j.cgh.2022.06.028 PMC 바로가기
Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX)Article Published on 2022-10-062022-11-15 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Ad26.COV2.S ANCA-associated vasculitis anti-CD20 antibody antibody level Antibody titre approved AZD1222 B cell B-cell B-cells blood sample case-control study CD19+ COVID-19 COVID-19 vaccine dose ELISA evaluated examined Factor first vaccination Frame help humoral humoral immune response immunogenicity Immunoglobulin Improved increased risk Inflammatory International mAb Moderna outcomes parameter Patient quantified RA reduced regimen rheumatic disease rituximab RNA-1273 RTX SARS-CoV-2 severe COVID-19 synchronization the patient therapeutic therapy treated Treatment Univariate analysis vaccination Vaccine [DOI] 10.1093/rheumatology/keac036 PMC 바로가기
Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research PartnershipArticle Published on 2022-10-062022-11-15 Journal: Vaccine [Category] 진단, [키워드] adjusted hazard ratio Administered Adults BNT162b2 clinical trial Cohort cohort study Community Community study confidence interval COVID-19 COVID-19 vaccine COVID-19 vaccines dose evaluated Evidence feasibility females first vaccination immunogenic Infection less male participant mRNA mRNA-1273 North not affect notable Older participant partnership point-of-care receiving Reporting SARS-CoV-2 SARS-CoV-2 serology second vaccination Seroconversion seroconversion rate seroconvert serology shown Symptom [DOI] 10.1016/j.vaccine.2022.09.021 PMC 바로가기
Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational studyArticle Published on 2022-10-012022-11-15 Journal: Breast cancer research and treatment [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Affect Breast Breast cancer breast cancer patient breast cancer patients Cancer cancer treatment CDK4/6 Chemotherapy collected COVID-19 Efficacy enrolled epidermal first vaccination five group growth factor Infection Infection prevention inhibitor inhibitors investigated Japan lowest neutralizing antibody Neutralizing antibody titer Omicron variant pandemic Patient Prevent prospective observational study raising receptor reduction reduction in SARA-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 variant second vaccination Seroconversion seroconversion rate serological response serum sample stratified suggested Support the patient the SARS-CoV-2 therapy Treatment vaccination vaccination efficacy Vaccine variant wild-type [DOI] 10.1007/s10549-022-06693-2 PMC 바로가기
SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal studyArticle Published on 2022-09-142022-11-15 Journal: Scientific Reports [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome BNT162b2 vaccine booster dose Cellular immune response changes in conducted coronavirus coronavirus disease COVID-19 demonstrated dose first vaccination follow-up period highest hospital humoral humoral immune response IgG IgG antibody immune response neutralization Neutralizing activity neutralizing antibody no correlation performed receiving SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 spike second vaccination serological Seven significantly sustained T cell T cell assay T cell response T cell responses the vaccine vaccination [DOI] 10.1038/s41598-022-19581-y PMC 바로가기
Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in JapanArticle Published on 2022-09-092022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] Abbott acute respiratory syndrome Adults age anti-RBD Anti-RBD antibody anti-RBD antibody response anti-receptor-binding domain anti-SARS-CoV-2 antibody Anti-SARS-CoV-2 S antibody Antibody Response Antibody titer Architect Architect SARS-CoV-2 IgG II Quant assays blood sample BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine collected comparable Coronavirus-2 correlation dose Elecsy Elecsys Elecsys Anti-SARS-CoV-2 S evaluated first vaccination geometric GMT GMT ratio GMTs healthcare healthy immunoassay immunoassays Japan Kinetics mRNA vaccine no significant difference Older age Participants prospective cohort study RBD Roche Diagnostics SARS-CoV-2 SARS-CoV-2 IgG second vaccination Sex significantly lower Spearman vaccination were measured [DOI] 10.1016/j.vaccine.2022.08.018 PMC 바로가기
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccinationArticle Published on 2022-09-012022-11-15 Journal: RMD Open [Category] SARS, 진단, [키워드] activated Activation antibody Autoimmune Autoimmune diseases Cellular immune response cellular response Combination correlated COVID-19 COVID-19 vaccination csDMARD cytokine cytokine profile drug drugs evaluated female first vaccination Frequency Heterologous highest humoral IgG immunosuppressive immunosuppressive therapy Inflammatory inhibitor investigated majority marker median age medications methotrexate monotherapy mRNA-based vaccine MTX Neutralising Antibodies neutralising antibody no difference not significant outcome Patient psoriatic arthritis quantification receiving rheumatic disease rheumatoid arthritis SARS-CoV-2 second vaccination Seroconversion spike-protein spondyloarthritis T-cell T-cell immunity T-lymphocyte T-lymphocyte subsets Therapies therapy titre treated vaccination [DOI] 10.1136/rmdopen-2022-002293 PMC 바로가기